N=1.831n=3.739n=3.374n=15.904n=13.297n=2.081 BP stratification according with 2003 ESH/ESC guidelines in Italian hypertensive patients included in population.

Slides:



Advertisements
Similar presentations
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.
Advertisements

THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Bridget Dillon February 11,  Cardiovascular disease affects the heart and circulatory system. It is often a result of blockages of blood vessels.
CVD risk estimation and prevention: An overview of SIGN 97.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP
Diabetes Mellitus Type 2
The concept of Diabetes & CV risk: A lifetime risk challenge
Type 2 diabetes and high blood pressure How explosive is the cocktail?
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
OPTIMAL BLOOD PRESSURE LEVELS IN ELDERLY PERSONS IN THE REASONS FOR GEOGRAPHIC AND RACIAL DIFFERENCES IN STROKE (REGARDS) COHORT STUDY Maciej Banach*,
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
Tt HRB Centre for Health and Diet Research The burden of hypertension Ivan J Perry, Dept. of Epidemiology and Public Health, University College Cork. Institute.
Hypertension By Dr. Nagwa Eid Saad Prof. Of Internal Medicine & Family Medicine In Cairo University.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
William B. Kannel, MD, FACC Former Director, Framingham Heart Study
DECREASING SLEEP-TIME BLOOD PRESSURE DETERMINED BY AMBULATORY MONITORING REDUCES CARDIOVASCULAR RISK Ramón C. Hermida, PhD; Diana E. Ayala, MD, MPH, PhD;
Blood Pressure Control By Randomized Drug Group In ALLHAT William C. Cushman, Charles E. Ford, Paula T. Einhorn, Jackson T. Wright, Jr., Richard A. Preston,
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Kotseva K, et al. Eur J Cardiovasc Prev Rehabil 2009 Mar 12 [Epub]
Epidemiology of CVD in the Elderly Karen P. Alexander MD Duke University Medical Center Duke Clinical Research Institute Disclosures: (1) Minor Research:
Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.
10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Blood pressure control in primary health care WORKSHOP
Clinical Trial Results. org Long-Term Prognosis Associated with Coronary Calcification Matthew J. Budoff, MD, Leslee J. Shaw, PhD, Sandy T. Liu, Steven.
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
1 Current & New treatment strategies to address CV Risk.
Utilization Of Lipid-lowering Therapy In Hypertensive Patients In The United States Simon S.K. Tang, MPH* Sean Candrilli, MS** Lizheng Shi, PhD* *Department.
Pai JK et al. N Engl J Med 2004; 351: Relative CHD risk by increasing baseline CRP plasma levels,* relative to CRP
中国农村心血管病防治面临的挑战 Challenges in prevention and control of CVD in Rural China Yangfeng Wu, MD, PhD The George Institute for Global Health at Peking University.
To assess the prognostic value of variability in home-measured blood pressure (BP) and heart rate (HR) in a general population. Objective: Methods: BP.
How can you estimate simply the cardiovascular risk of your patients?
לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
VBWG Predictor of CV Events and Mortality in Postmenopausal Women: Leukocyte Count.
A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.
Innovations in Management of Cardiovascular Disease for Global Health
INTERHEART: Focus on 9 risk or protective factors
New Guidelines for Myocardial Ischemia Management.
SPRINT What Remains Unanswered? Where Do We Go From Here? Embargoed Until 2 p.m. ET, Monday, Nov. 9, 2015.
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
2007 Hypertension as a Public Health Risk January, 2007.
Part 3. Diabetes Report Card: HbA 1c Levels in the United States Hoerger TJ, et al. Diabetes Care. 2008;31: Patients (%) HbA 1c (%)
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Antonio Coca, MD, PhD, FRCP, FESC
Dr John Cox Diabetes in Primary Care Conference Cork
a cautionary note from SPRINT
a cautionary note from SPRINT
Obesity Hypertension and Endothelial Dysfunction in Pediatric Patients
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
Baseline Demographic and Clinic Variables According to Office vs 24-Hour or Home BP Giuseppe Mancia, et al. Hypertension 2006;47;
What’s New in the 2013 ESC/ESH Hypertension Guideline
Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH): Design Randomized, double-blind.
Section VIII. Ambulatory BP Measurement
Managing Hard-To-Treat Hypertension: What Every Physician Should Know
اتجاهات أنماط المرض بين السكان. المراحل الأربع للتحول الوبائى.
Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.
Franklin SS, et al. Circulation 2009;119:243-50
Diabetes Pandemic. The Economics of Managing Patients With Diabetes and Coronary Artery Disease: A Payer Perspective.
Life expectancy and baseline BP: Male participants
Prevalence and costs of treating uncomplicated stage 1 hypertension in primary care: a cross-sectional analysis by James P Sheppard, Kate Fletcher, Richard.
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
A: Mean wall motion score index (95% CI) in patients with first myocardial infarction segregated by Hp type. A: Mean wall motion score index (95% CI) in.
Risk differences for incident stroke, coronary heart disease (CHD), and cardiovascular mortality (per 1000 person-years) by clinical risk factor in the.
Mean BP by visit - all patients
Section 6: Update on lipid treatment guidelines
Adjusted ORs of increasing severity of heartburn at follow-up in reference to baseline from model adjusted for BMI category, CVD history, BDI score >11,
Stroke Prevention: An Evidence-Based Update
Presentation transcript:

n=1.831n=3.739n=3.374n=15.904n=13.297n=2.081 BP stratification according with 2003 ESH/ESC guidelines in Italian hypertensive patients included in population and clinical surveys Volpe M, et al. J Hypertension 2007;25(7):1491-8

n=9.382 (17.8%) n= (44.0%) n= (38.2%) n=9.382 (17.8%) n= (44.0%) n= (38.2%) Systolic BP levels (mmHg)Diastolic BP levels (mmHg) Department Internal Medicine/Cardiology Hypertension Centers General Practitioners Department Internal Medicine/Cardiology Hypertension Centers General Practitioners Baseline BP levels according in Italian hypertensive patients included in population and clinical surveys Volpe M, et al. J Hypertension 2007;25(7):1491-8

Multiple Independent Risk Factors Management (Silo Approach) Integrated Identification and management of Risk Factors contributing to CVD Risk (Global Approach) Hypertension Hypercholesterolemia Diabetes Traditional CVD Perspective New CVD Risk Perspective New CVD Risk Perspective age sex smoking Diabetes Mellitus Hyper Choleste rolemia Organ Damage Hypertension New Targets and Goals for Therapy New Targets and Goals for Therapy Reduction of Total CVD Risk Volpe M, et al. J Human Hypertens 2007; in press Modern Strategy for CVD Prevention Integrated Guidelines for Global CV Reduction